| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 54.94 | -0.14 (-0.25%) | 37.26 - 55.47 | 4.8 thousand (Below Avg) |
Market data as of 10:26AM 05/21/13. Quotes are delayed by at least 15 min.
| Open | 54.95 |
|---|---|
| Previous Close | 55.08 |
| Day's Range | 54.79 - 54.98 |
| Market Cap | 1.3B |
| Avg Volume (10 Day) | 64.9K |
| Price/Earnings (Trailing 12 Mo.) | 51.0x |
| Earnings Per Share (Trailing 12 Mo.) | 1.08 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Neogen launches comprehensive cattle genomic test
PR Newswire - Monday 05/06/2013 8:45 AM ET
| NEOG | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 11.71% | |
| Net Income Growth (1yr) | 16.25% | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | 1.96% | |
| Price/Sales | 6.59 |
| Company | Last | Change |
|---|---|---|
| Abaxis Inc | 44.35 | -0.73% |
| Meridian Bioscience Inc | 21.70 | -0.69% |
| Quidel Corp | 22.70 | -0.66% |
| AMAG Pharmaceuticals Inc | 24.86 | -0.30% |
| Synta Pharmaceuticals Corp | 7.29 | -1.88% |
Data is delayed by at least 15 min.